DEVELOPING TREATMENT ATTRIBUTES FOR A PATIENT PREFERENCE SURVEY: A QUALITATIVE MULTINATIONAL STUDY IN MULTIPLE MYELOMA
Author(s): ,
Rosanne Janssens
Affiliations:
Department of Pharmaceutical and Pharmacological Sciences,KU Leuven,Leuven,Belgium
,
Tamika Lang
Affiliations:
Myeloma Patients Europe,Brussels,Belgium
,
Ana Vallejo
Affiliations:
Myeloma Patients Europe,Brussels,Belgium
,
Jayne Galinsky
Affiliations:
Myeloma Patients Europe,Brussels,Belgium
,
Ananda Plate
Affiliations:
Myeloma Patients Europe,Brussels,Belgium
,
Kate Morgan
Affiliations:
Myeloma Patients Europe,Brussels,Belgium
,
Elena Cabezudo
Affiliations:
Department of Haematology,H. Moises Broggi / ICO-Hospitalet,Barcelona,Spain
,
Raija Silvennoinen
Affiliations:
Department of Hematology,Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki,Helsinki,Finland
,
Daniel Coriu
Affiliations:
'Carol Davila' University of Medicine and Pharmacy and Fundeni Clinical Institute,Bucharest,Romania
,
Sorina Badelita
Affiliations:
Fundeni Clinical Institute,Bucharest,Romania
,
Ruxandra Irimia
Affiliations:
'Carol Davila' University of Medicine and Pharmacy and Fundeni Clinical Institute,Bucharest,Romania
,
Minna Anttonen
Affiliations:
Association of Cancer Patients in Finland,Helsinki,Finland
,
Riikka-Leena Manninen
Affiliations:
Association of Cancer Patients in Finland,Helsinki,Finland
,
Elise Schoefs
Affiliations:
Department of Pharmaceutical and Pharmacological Sciences,KU Leuven,Leuven,Belgium
,
Martina Vandebroek
Affiliations:
Faculty of Economics and Business,KU Leuven,Leuven,Belgium
,
Anneleen Vanhellemont
Affiliations:
University Hospital Leuven,Leuven,Belgium
,
Michel Delforge
Affiliations:
University Hospital Leuven,Leuven,Belgium
,
Hilde Stevens
Affiliations:
Institute for Interdisciplinary Innovation in healthcare (I3h),Université Libre de Bruxelles (ULB),Brussels,Belgium
,
Steven Simoens
Affiliations:
Department of Pharmaceutical and Pharmacological Sciences,KU Leuven,Leuven,Belgium
Isabelle Huys
Affiliations:
Department of Pharmaceutical and Pharmacological Sciences,KU Leuven,Leuven,Belgium
EHA Library. Janssens R. 06/09/21; 324913; EP1192
Rosanne Janssens
Rosanne Janssens
Contributions
Abstract
Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP1192

Type: E-Poster Presentation

Session title: Quality of life, palliative care, ethics and health economics

Background
Patient preferences have become an important focus for inclusion in the drug development, regulatory, and reimbursement process for multiple myeloma (MM) treatments (Postmus et al, 2018; Fifer et al, 2020). Over the last decade there has been a rapid development of new medicines for MM, all with varying safety and efficacy profiles. Therefore, the need for a clear and standardized methodology for collection of patient preference data is important. 

Aims
This study aimed to understand which characteristics of treatment MM patients find most important and should be included as attributes in a subsequent (quantitative) preference survey.

Methods
This research incorporates a literature review and qualitative discussions with patients to formulate attributes for inclusion in a subsequent quantitative patient preference survey. This qualitative study involved: i) a scoping literature review, ii) discussions with MM patients (n=24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique (NGT), and iii) a qualitative thematic analysis with multi-stakeholder discussions.

Results
After completion of the literature review, a patient consensus on MM treatment attributes was reached using NGT. Thematic analysis generated the following treatment attributes for inclusion in the subsequent quantitative patient preference survey: i) life expectancy, ii) life-threatening side-effects (such as the development of another cancer), iii) treatment response (i.e., a reduction of cancer signs), iv) nerve or bone problems affecting movement (such as fractures), v) thinking problems (such as concentration problems), vi) increased susceptibility to infections, vii) reduced energy, viii) pain (such as bone pain), ix) emotional problems (such as mood changes), x) eating and digestive problems (such as incontinence), and xi) vision problems (such as blurred vision).

Conclusion
Obtaining patient insights for inclusion in subsequent quantitative preference studies requires several steps. This study highlights the importance of the incorporation of the qualitative portion of a patient preference study, to ensure sensitive and appropriate attribute selection. This study illustrates that patients focus not only on treatment efficacy, but also value a reduction of MM-related symptoms and side effects.

Keyword(s): Multiple myeloma, Qualitative

Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP1192

Type: E-Poster Presentation

Session title: Quality of life, palliative care, ethics and health economics

Background
Patient preferences have become an important focus for inclusion in the drug development, regulatory, and reimbursement process for multiple myeloma (MM) treatments (Postmus et al, 2018; Fifer et al, 2020). Over the last decade there has been a rapid development of new medicines for MM, all with varying safety and efficacy profiles. Therefore, the need for a clear and standardized methodology for collection of patient preference data is important. 

Aims
This study aimed to understand which characteristics of treatment MM patients find most important and should be included as attributes in a subsequent (quantitative) preference survey.

Methods
This research incorporates a literature review and qualitative discussions with patients to formulate attributes for inclusion in a subsequent quantitative patient preference survey. This qualitative study involved: i) a scoping literature review, ii) discussions with MM patients (n=24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique (NGT), and iii) a qualitative thematic analysis with multi-stakeholder discussions.

Results
After completion of the literature review, a patient consensus on MM treatment attributes was reached using NGT. Thematic analysis generated the following treatment attributes for inclusion in the subsequent quantitative patient preference survey: i) life expectancy, ii) life-threatening side-effects (such as the development of another cancer), iii) treatment response (i.e., a reduction of cancer signs), iv) nerve or bone problems affecting movement (such as fractures), v) thinking problems (such as concentration problems), vi) increased susceptibility to infections, vii) reduced energy, viii) pain (such as bone pain), ix) emotional problems (such as mood changes), x) eating and digestive problems (such as incontinence), and xi) vision problems (such as blurred vision).

Conclusion
Obtaining patient insights for inclusion in subsequent quantitative preference studies requires several steps. This study highlights the importance of the incorporation of the qualitative portion of a patient preference study, to ensure sensitive and appropriate attribute selection. This study illustrates that patients focus not only on treatment efficacy, but also value a reduction of MM-related symptoms and side effects.

Keyword(s): Multiple myeloma, Qualitative

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies